OA11385A - Formulations comprising dissolved paroxetine. - Google Patents

Formulations comprising dissolved paroxetine. Download PDF

Info

Publication number
OA11385A
OA11385A OA1200000153A OA1200000153A OA11385A OA 11385 A OA11385 A OA 11385A OA 1200000153 A OA1200000153 A OA 1200000153A OA 1200000153 A OA1200000153 A OA 1200000153A OA 11385 A OA11385 A OA 11385A
Authority
OA
OAPI
Prior art keywords
paroxetine
solid
carrier
capsule
solid dosage
Prior art date
Application number
OA1200000153A
Other languages
English (en)
Inventor
Ahmad Ghazawi
Graham Stanley Leonard
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of OA11385A publication Critical patent/OA11385A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA1200000153A 1997-11-21 2000-05-19 Formulations comprising dissolved paroxetine. OA11385A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9724544.3A GB9724544D0 (en) 1997-11-21 1997-11-21 Novel Formulation

Publications (1)

Publication Number Publication Date
OA11385A true OA11385A (en) 2004-01-27

Family

ID=10822374

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000153A OA11385A (en) 1997-11-21 2000-05-19 Formulations comprising dissolved paroxetine.

Country Status (24)

Country Link
EP (1) EP1033986A1 (fr)
JP (1) JP2001523718A (fr)
KR (1) KR20010032320A (fr)
CN (1) CN1279608A (fr)
AP (1) AP2000001821A0 (fr)
AR (1) AR015485A1 (fr)
AU (1) AU1168099A (fr)
BG (1) BG104527A (fr)
BR (1) BR9814220A (fr)
CO (1) CO4970832A1 (fr)
DZ (1) DZ2658A1 (fr)
EA (1) EA200000552A1 (fr)
GB (1) GB9724544D0 (fr)
HU (1) HUP0100580A3 (fr)
IL (1) IL136106A0 (fr)
MA (1) MA24704A1 (fr)
NO (1) NO20002590L (fr)
OA (1) OA11385A (fr)
PE (1) PE20000381A1 (fr)
PL (1) PL340555A1 (fr)
SK (1) SK7342000A3 (fr)
TR (1) TR200001423T2 (fr)
WO (1) WO1999026625A1 (fr)
ZA (1) ZA9810637B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810180D0 (en) * 1998-05-13 1998-07-08 Smithkline Beecham Plc Novel formulation
CA2367402C (fr) * 1999-03-12 2010-11-23 Basf Aktiengesellschaft Forme pharmaceutique stable pour anhydrate de paroxetine
DE60004768T2 (de) 1999-07-01 2004-07-08 Italfarmaco S.P.A. Komplexe von paroxetin mit cyclodextrin oder cyclodextrin derivaten
DE19930454A1 (de) * 1999-07-02 2001-01-04 Knoll Ag Feste Paroxetin enthaltende Zubereitungen
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
WO2003055468A1 (fr) * 2001-12-21 2003-07-10 Shire Laboratories Inc. Formulation de gelule a administration orale presentant une stabilite physique accrue
SE0200475D0 (sv) * 2002-02-15 2002-02-15 Ltp Lipid Technologies Provide Oral farmaceutisk beredning
WO2006119779A2 (fr) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S Composition pharmaceutique comprenant un antagoniste de l'aldosterone
EP2510924B1 (fr) * 2009-12-08 2014-10-08 IL Hwa Co., Ltd DISPERSIONS SOLIDES CONTENANT DU 20-O-ß-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031197A1 (fr) * 1995-04-03 1996-10-10 Abbott Laboratories Melanges homogenes de medicaments fondant a basse temperature et d'additifs, destines a une liberation lente
AU730532B2 (en) * 1997-01-15 2001-03-08 Smithkline Beecham Plc Paroxetine compositions

Also Published As

Publication number Publication date
NO20002590D0 (no) 2000-05-19
EA200000552A1 (ru) 2000-10-30
SK7342000A3 (en) 2000-12-11
NO20002590L (no) 2000-07-19
IL136106A0 (en) 2001-05-20
WO1999026625A1 (fr) 1999-06-03
ZA9810637B (en) 2000-05-22
PE20000381A1 (es) 2000-05-07
GB9724544D0 (en) 1998-01-21
AU1168099A (en) 1999-06-15
PL340555A1 (en) 2001-02-12
MA24704A1 (fr) 1999-07-01
JP2001523718A (ja) 2001-11-27
CO4970832A1 (es) 2000-11-07
HUP0100580A2 (hu) 2002-04-29
DZ2658A1 (fr) 2003-03-22
EP1033986A1 (fr) 2000-09-13
AP2000001821A0 (en) 2000-06-30
CN1279608A (zh) 2001-01-10
AR015485A1 (es) 2001-05-02
TR200001423T2 (tr) 2000-10-23
BR9814220A (pt) 2001-12-26
BG104527A (en) 2001-04-30
KR20010032320A (ko) 2001-04-16
HUP0100580A3 (en) 2002-05-28

Similar Documents

Publication Publication Date Title
US6524615B2 (en) Controlled release pharmaceutical composition
RU2278657C2 (ru) Предконцентрат микроэмульсии
US8293270B2 (en) Lipophilic vehicle-based dual controlled release matrix system
US6491950B1 (en) Controlled release pharmaceutical composition
JP2003520772A (ja) 脂質調節剤を含む新規製剤
JP2009197015A (ja) ハードシェルカプセル剤のためのイブプロフェン溶液
AU2019329905B2 (en) Vitamin D pediatric dosage forms, methods of making and using
OA11385A (en) Formulations comprising dissolved paroxetine.
EP1330244B1 (fr) Compositions comprenant des composes de modafinil
AU2013213706B2 (en) An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
US20020032220A1 (en) Formulations comprising dissolved paroxetine
CA2310407A1 (fr) Formulations contenant de la paroxetine dissoute
MXPA00005030A (en) Formulations comprising dissolved paroxetine
JP2003504392A (ja) 新規医薬製剤
CZ20001876A3 (cs) Prostředky obsahující rozpuštěný paroxetin
KR20020039354A (ko) 바소프레신 길항제 제형 및 방법
AU2002211677B2 (en) Compositions comprising modafinil compounds
WO2014033291A1 (fr) Compositions pharmaceutiques comprenant un principe actif
AU2002211677A1 (en) Compositions comprising modafinil compounds